<DOC>
	<DOC>NCT02229786</DOC>
	<brief_summary>Study to evaluate efficacy and tolerability of Buscopan® plus versus Buscopan®, paracetamol, and placebo in patients with painful gastric or intestinal spasms.</brief_summary>
	<brief_title>Efficacy and Tolerability of Buscopan Plus in Painful Gastric or Intestinal Spasms</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Butylscopolammonium Bromide</mesh_term>
	<mesh_term>Scopolamine Hydrobromide</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Male and female patients Age: 18 70 years Diagnosis: recurring painful gastric or intestinal spasms such as occur e.g. in irritable bowel syndrome, which are not organic in origin, have been present for at least 2 months, and are serious enough to interfere with everyday activities Patient briefing as per §§ 40/41 of the Arzneimittelgesetz (AMG) and patient's declaration of Informed Consent in writing, in agreement with Good Clinical Practice (GCP) and current legal requirements A pain assessment of 3 cm or more on the visual analog scale on at least one of the 2 days immediately preceding the second visit Painful gastric or intestinal spasms of organic origin such as Crohn's disease, ulcerative colitis, lactose intolerance Tumour pain/malignant growths Patients with other severe pain states of organic origin (e.g. biliary colic) Mechanical stenoses of the gastrointestinal tract, megacolon Urinary retention associated with mechanical stenoses of the urinary tract (e.g. in prostate adenoma) Narrowangle glaucoma Tachyarrhythmia Myasthenia gravis Glucose 6phosphate dehydrogenase deficiency (danger of haemolytic anaemia) Known hypersensitivity to Nbutylscopolammonium bromide or paracetamol Severe liver impairment (e.g. through chronic alcohol abuse, hepatitis): a) SerumGlutamateOxalacetatTransaminase/ Aspartate Aminotransferase (SGOT) higher than four times the norm b) Bilirubin &gt; 3 mg/dl c) Quick's value &lt; 70% MeulengrachtGilbert syndrome (metabolic disturbance with episodes of jaundice) Severe kidney failure: creatinine &gt; 2 mg/dl Known depression or known mental illness, anxiety disturbance Concomitant intake of analgesics, nonsteroidal antiinflammatory drugs (NSAIDs) and/or spasmolytics, anticholinergics, nitrates Concomitant medication affecting gastrointestinal motility Regular (daily) use of laxatives Drugs that induce liver enzymes Concomitant administration of chloramphenicol Use of narcotics Antidepressant treatment or treatment with psychoactive drugs Pregnancy and lactation Alcohol abuse (more than 60 g alcohol/day) Frequent vomiting that might prevent adequate absorption of the active ingredient after the filmcoated tablet is taken Patients who are unlikely to be able to keep the examination appointments or cannot reliably take the study medication regularly Simultaneous participation in another clinical study Patients who are not trained in the VAS (PI) at Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>